Changes in Beneficial Ownership · 4
Invivyd, Inc.
IVVDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-30
- Issuer
- Invivyd, Inc.
- Issuer CIK
- 0001832038
- Trading symbol
- IVVD
Reporting owner 1
- Name
- Elia Marc
- Reporting owner CIK
- 0001830496
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O INVIVYD, INC., 205 CHURCH STREET, NEW HAVEN, CT, 06510
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 0.9645 | 2026-08-30 | A · Form 4 | 10,700,000 | A | 0 | [F1] | 2036-08-29 | Common Stock | 10,700,000 | 10,700,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of August 30, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.↩ 1
Remarks
Exhibit 24.1: Power of Attorney
Signature 1
- Signed
- /s/ Jill Andersen attorney-in-fact for Marc Elia
- Date
- 2026-09-01
Filed exhibits
- EX-24.1 ↗ivvd-ex24_1.htm
Company context
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.